MCA in Patients with Breast Cancer: Correlation with CEA and CA15-3

International Journal of Biological Markers - Tập 5 Số 1 - Trang 14-21 - 1990
Rafael Molina1, Xavier Filella2, P. Mengual2, Miquel Prats3, Gabriel Zanón4, Michael J. Daniels5, Ballesta Am2
1Laboratory of Clinical Biochemistry (Unit for Cancer Research), School of Medicine, Hospital Clinico, Barcelona, Spain.
2Laboratory of Clinical Biochemistry (Unit for Cancer Research), Barcelona - Spain
3Department of Surgery (Senology Unit), Barcelona - Spain
4Department of Obstetrics and Gynaecology, Barcelona - Spain
5Department of Oncology Unit School of Medicine, Hospital Clinico, Barcelona - Spain

Tóm tắt

MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4 % of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III–IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p < 0.02). Inpatients with metastases the sensitivity was about 77.5%, 70% and 65.1% respectively for MCA, CA15-3 and CEA. Sensitivity using the three tumor markers was not significantly better than with only two of them

Từ khóa


Tài liệu tham khảo

10.1016/B978-0-08-031739-7.50163-4

10.1089/hyb.1984.3.223

10.1007/BF01949996

Bonfrer J.M.G., 1986, I markers tumorali in ginecologia., 271

10.1177/172460088800300302

10.1177/172460088800300304

Molina R., 1985, I marker tumorali in ginecologia., 459

Molina R., 1986, Neoplasia, 3, 85

Zenklusen H.R., Virchows Arch

10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

International Union Against Cancer (UICC)., 1985, TNM classification of malignant tumors, 4

10.1038/256495a0

10.1172/JCI110380

Koprowski H., 1981, Science, 53, 212

10.1159/000233384

10.1038/bjc.1984.254

Einhorn N., 1986, Obstet Gynecol, 67, 414

10.1093/clinchem/29.3.549

10.1016/B978-0-08-031739-7.50157-9

10.1002/1097-0142(19890201)63:3<490::AID-CNCR2820630317>3.0.CO;2-4

10.1002/1097-0142(197809)42:3+<1412::AID-CNCR2820420805>3.0.CO;2-8

10.1002/1097-0142(197809)42:3+<1399::AID-CNCR2820420803>3.0.CO;2-P

10.1016/0009-8981(86)90278-0

Hirai H., 1982, Biochemical markers in cancer., 25

Molina R., Clinical Chem.

Gion M., 1988, Tumor markers in breast cancer, evaluation in serum and in tissue.

Cooper E.H., 1988, An evaluation of MCA in breast cancer.

Molina R., 1986, I markers tumorali in ginecologia., 473

Molina R., 1985, Protides of the biological fluids., 847

10.1002/1097-0142(197405)33:5<1246::AID-CNCR2820330509>3.0.CO;2-O

10.1002/1097-0142(197809)42:3+<1507::AID-CNCR2820420823>3.0.CO;2-W

Thông tin
Thông tin xuất bản

International Journal of Biological Markers

Tập 5 Số 1

14-21

Thông tin tác giả